BioMed Research International / 2020 / Article / Tab 2

Research Article

Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma

Table 2

Combination of ribociclib and IFN-α is synergistic in inhibiting the proliferation of some RCC cell lines.

Combination index (CI)
786-0Caki-2769-PA704ACHNSW839UM-RC-2Caki-1A489

C120
C150
C180

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.